Form 4: Elevance Health CAO Reports Stock Transactions

Elevance Health's CAO and Controller, Ronald W. Penczek, reported the acquisition of restricted stock units and stock options, alongside the disposal of shares for tax liabilities.

Summary

• Ronald W. Penczek, CAO & Controller of Elevance Health, Inc., reported multiple transactions involving the company's common stock and derivative securities.
• Disposed of 131 shares of Common Stock on March 2, 2026, at a price of $294.07 per share to satisfy tax liabilities related to equity vesting.
• Acquired 426 restricted share units on March 2, 2026, which are scheduled to vest in three annual installments of 142 shares each, beginning on March 2, 2027.
• Acquired 1,701 restricted share units on March 2, 2026, with vesting scheduled as 850 shares on March 2, 2027, and 851 shares on March 2, 2028.
• Acquired 266 performance-based restricted share units on March 2, 2026, for which restrictions had already lapsed on the same date.
• Disposed of an additional 37 shares of Common Stock on March 3, 2026, at a price of $284.03 per share, also for tax liability payment.
• Acquired 1,677 employee stock options on March 2, 2026, with an exercise price of $294.07. These options become exercisable in three annual installments of 559 shares each, starting on March 2, 2027, and expire on March 2, 2036.
• Following these transactions, the beneficial ownership of non-derivative common stock is 4,099 shares directly.
• The beneficial ownership of derivative employee stock options is 1,677 options directly.
• The reported balance of non-derivative shares includes shares acquired through a dividend reinvestment plan on March 25, 2025 (7.06 shares), June 25, 2025 (6.14 shares), September 25, 2025 (7.18 shares), and December 19, 2025 (6.85 shares).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting ongoing executive compensation and retention through equity grants, which aligns management's interests with shareholders over the long term, despite minor tax-related share disposals.

Positives

• Acquisition of 426 restricted share units, vesting over three years, aligning executive interests with long-term company performance.
• Acquisition of 1,701 restricted share units, vesting over two years, further strengthening executive equity ownership.
• Acquisition of 266 performance-based restricted share units, indicating achievement of performance targets.
• Grant of 1,677 employee stock options, providing future equity participation and incentive for value creation.
• Continued participation in the company's dividend reinvestment plan, incrementally increasing share count.

Negatives

• Disposal of 131 shares of common stock at $294.07 and 37 shares at $284.03 to satisfy tax liabilities, resulting in a reduction of direct share ownership.

Future Outlook

The filing details future vesting schedules for restricted share units and exercisability dates for employee stock options, indicating a long-term incentive structure for the reporting person extending through March 2036.

Industry Context

StockSavvy.ai notes that these transactions are routine insider compensation and tax-related activities, common across all industries for executives receiving equity-based awards. They do not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The equity grants align the executive's interests with long-term shareholder value. Tax-related disposals are a routine part of equity compensation.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent for other senior management equity awards.

Next Steps

• Vesting of 142 restricted shares on March 2, 2027, March 2, 2028, and March 2, 2029.
• Vesting of 850 restricted shares on March 2, 2027, and 851 restricted shares on March 2, 2028.
• Employee stock options become exercisable in three annual installments of 559 shares each, beginning March 2, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the grant of restricted stock units and stock options, and subsequent share disposals to cover tax liabilities. These transactions are expected and do not provide new material information that would significantly alter the investment thesis for Elevance Health. The grants align executive incentives with long-term company performance, which is a positive, but the overall impact on the stock's fundamental value or short-term price action is negligible. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell based solely on this information.

Keywords

Elevance Health, ELV, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation, Ronald W. Penczek, CAO, Controller, Share Disposal, Share Acquisition, Dividend Reinvestment